Overview Quote
Stock Activity
| Day Low - High | 31.31 - 33.64 |
| 52wk Low - High | 20.04 - 37.40 |
| Previous Close | 32.53 |
| Avg. Volume | 1,149,398 |
| Industry | MED-BIOMED/GENE |
| Market Cap | 1.75 B |
| Div - Yield | 0.00 - 0.00 |
| Beta | 0.81 |
| PE (Forward) | 34.83 |
| Current Year Est. | 0.93 |
| Quarterly Earnings ESP |
-3.23% |
Premium research
Zacks Rank
|
3 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
95 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Company Description
Medicines Company acquires, develops and commercializes biopharmaceutical products in late stages of development. U.S. Food and Drug Administration intends to approve its first product, Angiomax, for use in the treatment of patients with unstable angina undergoing coronary balloon angioplasty. The company is also developing Angiomax for additional potential applications for use in the treatment of ischemic heart disease, a condition which occurs when organs receive an inadequate supply of oxygen as a result of decreased blood flow.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | 0.31 | 0.36 | 0.93 | 1.59 |
| Number of Estimates | 5 | 4 | 5 | 5 |
| Low Estimate | 0.29 | 0.30 | 0.76 | 0.84 |
| High Estimate | 0.34 | 0.40 | 1.04 | NA |
| Year Ago EPS | 0.39 | 0.33 | 1.64 | 0.93 |
| EPS Growth | -21.54% | 9.85% | -43.05% | 70.24% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| MEDICINES CO | MDCO | 32.53 | ![]() |
![]() |
| AETERNA ZENTARS | AEZS | 2.06 | ![]() |
![]() |
| ANIKA THERAPEUT | ANIK | 13.75 | ![]() |
![]() |
| GENTIUM SPA-ADR | GENT | 8.79 | ![]() |
![]() |
| AASTROM BIOSCI | ASTM | 0.57 | ![]() |
![]() |
| ACADIA PHARMA | ACAD | 13.42 | ![]() |
![]() |
| ACHILLION PHARM | ACHN | 7.74 | ![]() |
![]() |
| ADDEX THERA LTD | ADDXF | 6.62 | ![]() |
![]() |
| AFFYMAX INC | AFFY | 1.40 | ![]() |
![]() |
| ALEXION PHARMA | ALXN | 100.57 | ![]() |
![]() |
Sector:Medical>> Industry:MED-BIOMED/GENE
Zacks Commentary
Pediatric Approval for MDCO/BMY's Recothrom
May 15, 2013
Earnings Increase at The Medicines Co.
Apr 26, 2013
MDCO's Cangrelor Impresses
Mar 11, 2013
Encouraging News for Cubist Pharma
Mar 01, 2013
4Q Beat for The Medicines Co.
Feb 22, 2013
MDCO-BMY Deal Comes into Effect
Feb 11, 2013
Alnylam-MDCO Join for ALN-PCS
Feb 05, 2013
The Medicines Co. Acquires Incline
Jan 11, 2013
Financials
| EPS TTM | 1.69 |
| Sales | 559 |
| Net Income | 32 |
| Price/Earnings | 19.25 |
| Price/Book | 2.86 |
| Price/Cash Flow | 16.74 |
| Price/Sales | 2.98 |
News
Analysis of Relative Performance in the Pharmaceuticals Industry for Shares of Nektar Therapeutics (NKTR, CADX, MDCO, QCOR, TEVA) - Financial News Network Online - News Corner
May 23, 2013
Is There a Future for Small Pharma? - TheMotleyFool
May 23, 2013
Lumber Liquidators Leads Top 5 Small Cap Screen - Investors Business Daily
May 23, 2013
Medicines Co Makes a Move: Up 2.3% - Financial News Network Online - Market Movers
May 23, 2013
Stocks Ease To Mild Losses: Dollar Tree, HP Add Gains - Investors Business Daily
May 23, 2013
Stocks Stage Broad Advance; Bristol-Myers Leads Medicals - Investors Business Daily
May 22, 2013
Medicines Co Set to Possibly Rebound After Yesterday's Selloff of 5.34% - Comtex Smartrend(R)
May 21, 2013
Sellers Reduce Exposure to Shares of Medicines Co on 3.2x Above-Average Volume (MDCO) - Financial News Network Online - Unusual Volume
May 21, 2013
Broker Recommendations
| Current ABR | 1.50 |
| ABR (Last Week) | 1.50 |
| # of recs in ABR | 6 |
| Average Target Price | 37.92 |
| Industry Rank by ABR | 95 out of 265 |
| Rank in Industry | 36 out of 152 |

3